ADC Therapeutics SA (NYSE: ADCT)
Health Care · Biotechnology · CH
$1.04
+4.35% today · -67.7% 1Y
ADC Therapeutics SA (NYSE: ADCT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $127.23M and employs 191 people.
Over the last twelve months the share price has lost 67.7%, trading between 0.78 and 4.98.
Tweenvest scores ADC Therapeutics SA across four factors: quality 10/100, value 57/100. Its strongest factor is value.
ADCT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $127.23M
- Revenue (TTM)
- $79.58M
- P/E
- —
- EPS
- -0.65
- Dividend yield
- —
- Beta (5Y)
- 1.83
- 52-week high
- $4.98
- 52-week low
- $0.78
- Avg volume (3M)
- —
- Shares outstanding
- 127.67M
- Employees
- 191
- Next earnings
- —
About ADC Therapeutics SA
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors. The company maintains strategic collaboration and license agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. Founded in 2011, ADC Therapeutics S.A. has its headquarters located in Epalinges, Switzerland.
- ISIN
- CH0499880968
- Founded
- 2011
- Listed since
- May 18, 2020
- Exchange
- New York Stock Exchange
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.00 | +0.08% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.45 | +0.05% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.74 | -0.02% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €909.60 | +3.46% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $157.49 | -0.84% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.